- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00706355
A Study of PF-04217903 in Patients With Advanced Cancer
15 de junho de 2012 atualizado por: Pfizer
Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-4217903 in Patients With Advanced Cancer
PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells.
PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors.
This research study is the first time PF-04217903 will be given to patients.
PF-04217903 is taken by mouth daily.
Visão geral do estudo
Descrição detalhada
The study was prematurely discontinued due to a strategic development decision by Pfizer on 10FEB2012.
The decision to terminate was not based on any safety concerns.
Tipo de estudo
Intervencional
Inscrição (Real)
16
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Pfizer Investigational Site
-
Boston, Massachusetts, Estados Unidos, 02115
- Pfizer Investigational Site
-
Boston, Massachusetts, Estados Unidos, 02215
- Pfizer Investigational Site
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Pfizer Investigational Site
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Advanced solid tumors, histologically proven at diagnosis which is refractory to standard of care or for whom no standard of care therapy is available
- Adequate blood cell counts, normal kidney function, and performance status of 0 or 1
Exclusion Criteria:
- Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting study treatment
- Prior stem cell transplant
- Active or unstable cardiac disease or heart attack within 12 months of starting study treatment
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: 1
|
Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule.
Doses to be evaluated will range from 50 mg BID to 1000 mg BID.
A cycle is considered to be 21 days
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Maximum Tolerated Dose (MTD)
Prazo: Baseline up to 21 days after the start of each increased treatment dose
|
MTD: dose level at which 1 of 6 participants experienced dose-limiting toxicity (DLT) after 21 days of treatment (Cycle 1).
DLT: grade (Gr) 2 elevated creatinine, acute renal failure, Gr 3 thrombocytopenia with bleeding, hypertension (if unmanageable),Gr >=3 non-hematological non-disease-related (NDR) toxicities (except alopecia,Gr 3/4 hypophosphatemia, hyperuricemia), Gr 3/4 nausea, vomiting, diarrhea, Gr 4 neutropenia, thrombocytopenia lasting for >=7 days, febrile neutropenia, neutropenic infection, inability to deliver 80 percent of planned dose during Cycle 1 due to NDR toxicities.
|
Baseline up to 21 days after the start of each increased treatment dose
|
Recommended Phase 2 Dose (RP2D)
Prazo: Baseline up to 21 days after the start of each increased treatment dose
|
Baseline up to 21 days after the start of each increased treatment dose
|
|
Number of Participants With Dose-Limiting Toxicities (DLTs)
Prazo: Baseline up to 21 days after the start of each increased treatment dose
|
DLT includes Gr 2 elevated creatinine and acute renal failure, Gr 3 thrombocytopenia with bleeding, hypertension (if unmanageable), Gr >= 3 non-hematological non-disease-related (NDR) toxicities (except alopecia, Gr 3/4 hypophosphatemia, hyperuricemia), Gr 3/4 nausea, vomiting, diarrhea, Gr 4 neutropenia, thrombocytopenia lasting for >= 7 days, febrile neutropenia, neutropenic infection, inability to deliver at least 80 percent of planned dose during Cycle 1 due to NDR adverse events.
|
Baseline up to 21 days after the start of each increased treatment dose
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) for PF-04217903 and PF-04217903 Metabolite (PF-04328029)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hours (hrs) (just prior to evening dosing) post dose on Cycle (C) 1 Day (D) 1 and C2 D1
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hours (hrs) (just prior to evening dosing) post dose on Cycle (C) 1 Day (D) 1 and C2 D1
|
|
Minimum Observed Plasma Trough Concentration (Cmin) for PF-04217903 and PF-04217903 Metabolite (PF-04328029)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C2 D1
|
Participants did not receive 200 mg twice a day dose of study treatment for this specific measure.
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C2 D1
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-04217903 and PF-04217903 Metabolite (PF-04328029)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
|
Pre-dose Plasma Concentration (Ctrough) for PF-04217903 and PF-04217903 Metabolite (PF-04328029)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Participants did not receive 200 mg twice a day dose of study treatment for this specific measure.
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration [AUC(0-last)] for PF-04217903 and PF-04217903 Metabolite (PF-04328029)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Area Under the Curve From Time Zero to End of Dosing Interval [AUC(0-tau)] for PF-04217903 and PF-04217903 Metabolite (PF-04328029)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Area under the concentration-time profile from time zero to time tau (dosing interval), where tau is equal to 12 hours.
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Accumulation Ratio (Rac) for PF-04217903 and PF-04217903 Metabolite (PF-04328029)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C2 D1
|
Rac is obtained from AUCtau (Cycle 2 Day 1) divided by AUCtau (Cycle 1 Day 1).
Participants did not receive 200 mg twice a day dose of study treatment for this specific measure.
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C2 D1
|
Metabolite to Parent Ratio Area Under the Curve From Time Zero to End of Dosing Interval (MRAUCtau)
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Molar ratio of metabolite to parent area under the plasma concentration time-curve from zero (pre-dose) to end of dosing interval (MRAUCtau).
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C1 D1 and C2 D1
|
Apparent Oral Clearance (CL/F) for PF-04217903
Prazo: 0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C2 D1
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Participants did not receive 200 mg twice a day dose of study treatment for this specific measure.
|
0 (pre-dose), 1, 2, 4, 6, 8 and 12 hrs (just prior to evening dosing) post dose on C2 D1
|
Change From Baseline in Tumor Proliferation Using F-Fluoro-3'-Deoxy-3'-L-Fluorothymidine Positron Emission Tomography (FLT-PET) Imaging at Day 1 of Cycle 2
Prazo: Cycle 2 Day 1
|
F-fluoro-3'-deoxy-3'-L-fluorothymidine positron emission tomography (FLT-PET) imaging was used to assess the tumor proliferation in RP2D cohorts.
Results of the FLT-PET were scored according to the methods developed by the American College of Radiology Imaging Network (ACRIN).
|
Cycle 2 Day 1
|
Percentage of Participants With Objective Response (OR)
Prazo: Baseline until disease progression up to C2 D1
|
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response.
CR was defined as disappearance of all lesions (target and/or non target).
PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
|
Baseline until disease progression up to C2 D1
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de agosto de 2008
Conclusão Primária (Real)
1 de junho de 2011
Conclusão do estudo (Real)
1 de junho de 2011
Datas de inscrição no estudo
Enviado pela primeira vez
25 de junho de 2008
Enviado pela primeira vez que atendeu aos critérios de CQ
25 de junho de 2008
Primeira postagem (Estimativa)
27 de junho de 2008
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
25 de junho de 2012
Última atualização enviada que atendeu aos critérios de controle de qualidade
15 de junho de 2012
Última verificação
1 de junho de 2012
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- B0331002
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em PF-04217903
-
PfizerConcluído
-
PfizerConcluído
-
PfizerConcluído
-
PfizerConcluído
-
PfizerConcluído
-
University of FloridaConcluídoSintomas gastrointestinais | Frequência das fezes | Tempo de Trânsito GastrointestinalEstados Unidos
-
PfizerAinda não está recrutando